Relative change in SHBG at week 12 for TERN-501 monotherapy groups (placebo, n = 18; TERN-501 1 mg, n = 22 (P = 0.7471); TERN-501 3 mg, n = 19 (P = 0.0124); TERN-501 6 mg, n = 21 (P < 0.0001)). Dashed horizontal line at 120% represents clinically significant increases in SHBG 19. Statistical analysis was performed using a type III sum of squares ANCOVA model with treatment group as a fixed effect and baseline value as the covariate; comparison between groups was conducted at the two-sided, 0.05 level of significance. No adjustments for multiplicity were made. Error bars, s.e. * P < 0.05; *** P < 0.001 for TERN-501 monotherapy versus placebo.
